Richard K. Prins Sells 5,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the completion of the sale, the director now directly owns 31,471 shares in the company, valued at $1,535,784.80. This trade represents a 13.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $45.06 on Friday. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The stock’s 50-day moving average price is $48.42 and its 200 day moving average price is $44.34. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 15.02, a PEG ratio of 0.92 and a beta of 0.82. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Analyst Ratings Changes

A number of equities analysts have recently commented on AMPH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Piper Sandler cut their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $63.00.

Institutional Trading of Amphastar Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. TD Asset Management Inc increased its holdings in shares of Amphastar Pharmaceuticals by 67.4% in the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company’s stock valued at $67,663,000 after purchasing an additional 680,976 shares in the last quarter. Epoch Investment Partners Inc. raised its position in shares of Amphastar Pharmaceuticals by 35.1% in the second quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company’s stock valued at $43,154,000 after buying an additional 280,390 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 19.7% during the second quarter. American Century Companies Inc. now owns 740,408 shares of the company’s stock worth $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Millennium Management LLC grew its holdings in Amphastar Pharmaceuticals by 84.6% in the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company’s stock valued at $29,550,000 after buying an additional 338,653 shares during the period. Finally, Boston Trust Walden Corp acquired a new position in Amphastar Pharmaceuticals during the third quarter worth approximately $26,189,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.